Add to favorites

#Product Trends

ZOLL Lifevest Wearable Defibrillator to be Showcased at European Society of Cardiology Heart Failure Congress 2014

The LifeVest will be discussed during the following scientific sessions:

Nicole Bianco, PhD, ZOLL, will present “Wearable Cardioverter Defibrillator Use for Short-Term SCA Protection in Patients with Preserved LVEF Heart Failure,” Saturday, 17 May, 8:30 a.m., Poster Session 1, Poster Area.

Chingping Wan, MD, ZOLL, will present “Use of the Wearable Cardioverter Defibrillator in Patients with Infiltrative Disorders,” Tuesday, 20 May, 8:30 a.m., Rapid Fire Abstract Session, Agora Lecture Room.

Heart failure (HF) affects an estimated 15 million people in Europe.1 Patients newly diagnosed with HF have a high mortality rate, up to 40% in the first year, including a high risk of sudden cardiac death (SCD).2 Compared to the general population, SCD occurs 6-9 times more frequently in HF patients,3 and an acute event such as hospitalization for heart failure decompensation or myocardial infarction increases the SCD risk.4,5 Likewise, an HF patient''s condition can improve from the benefits of optimized medical therapy, which can require up to 3 months or more to stabilize.6

The LifeVest is worn by patients at risk for SCD, including patients with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest provides protection during their changing condition and while permanent SCD risk has not been established, allowing a patient''s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient''s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, and before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

Details

  • ZOLL Medical Corporation

    Keywords